Clarius Group LLC Decreases Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

Clarius Group LLC reduced its position in Scholar Rock Holding Co. (NASDAQ:SRRK) by 1.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 13,422 shares of the company’s stock after selling 258 shares during the period. Clarius Group LLC’s holdings in Scholar Rock were worth $580,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Scholar Rock by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock worth $25,000 after purchasing an additional 514 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after buying an additional 269 shares in the last quarter. Quarry LP grew its stake in Scholar Rock by 3,443.3% in the 3rd quarter. Quarry LP now owns 4,500 shares of the company’s stock valued at $36,000 after acquiring an additional 4,373 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in Scholar Rock in the 2nd quarter valued at about $100,000. Finally, Point72 DIFC Ltd acquired a new position in Scholar Rock during the second quarter worth about $103,000. 91.08% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, major shareholder Public Equities L.P. Invus sold 409,433 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $38.49, for a total transaction of $15,759,076.17. Following the completion of the transaction, the insider now owns 10,850,005 shares of the company’s stock, valued at $417,616,692.45. This represents a 3.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 19.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have issued reports on the stock. BMO Capital Markets upped their price target on shares of Scholar Rock from $34.00 to $38.00 and gave the company an “outperform” rating in a report on Friday, October 11th. JPMorgan Chase & Co. raised their price target on Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, October 14th. Piper Sandler boosted their price target on Scholar Rock from $28.00 to $42.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Truist Financial increased their price objective on Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, November 25th. Finally, Wedbush reissued an “outperform” rating and issued a $47.00 target price on shares of Scholar Rock in a research note on Thursday, January 9th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $40.43.

Scholar Rock Price Performance

SRRK stock opened at $43.13 on Monday. The stock has a market capitalization of $4.04 billion, a price-to-earnings ratio of -18.35 and a beta of 0.52. The stock’s fifty day simple moving average is $39.28 and its 200-day simple moving average is $23.08. Scholar Rock Holding Co. has a 52-week low of $6.76 and a 52-week high of $46.19. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.